• Smart Hydrogel with ROS Scavenging for Diabetic Wound Repair

  2026-05-28

  A multifunctional thermosensitive hydrogel integrating MnO₂ nanozymes and TGF-β1 demonstrates accelerated diabetic wound healing via targeted ROS scavenging and immune modulation. The study advances biomaterial design for chronic wound management and offers a promising translational avenue for clinical applications.

• NLRP10 Regulates Keratinocyte Survival and Differentiation i

  2026-05-28

  This study demonstrates that NLRP10 is essential for maintaining epidermal homeostasis by promoting keratinocyte survival, P63-dependent differentiation, and barrier function—processes disrupted in atopic dermatitis (AD). The findings provide mechanistic insight into how genetic variants affecting NLRP10 contribute to AD pathogenesis and identify NLRP10 as a potential therapeutic target for restoring skin barrier integrity.

• AR Heterogeneity Dictates Enzalutamide Response in Prostate

  2026-05-27

  This study reveals that heterogeneity in androgen receptor (AR) expression within prostate cancer drives divergent responses to castration and enzalutamide therapy. By dissecting AR+ and AR−/lo subpopulations, the research identifies distinct tumorigenic properties and therapeutic vulnerabilities, providing a framework for tailoring interventions in castration-resistant prostate cancer.

• Live-Dead Cell Staining Kit: Precision Cell Viability in Oxi

  2026-05-27

  Explore how the Live-Dead Cell Staining Kit enables accurate cell viability assays under oxidative stress, leveraging Calcein-AM Propidium Iodide staining. Discover unique insights linking cell survival analysis to advanced diabetic wound research.

• Intestinal TM6SF2 Deficiency Drives MASH via the Gut–Liver A

  2026-05-26

  This study reveals that intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis (MASH) by preserving gut barrier integrity and modulating host–microbe interactions. The findings identify lysophosphatidic acid (LPA) signaling as a mechanistic link between gut dysbiosis and hepatic inflammation, suggesting new therapeutic targets in metabolic liver disease.

• EPI-001: Advancing Androgen Receptor N-Terminal Domain Inhib

  2026-05-26

  EPI-001 stands apart as a robust androgen receptor N-terminal domain inhibitor, enabling precise dissection of AR signaling in advanced prostate and triple-negative breast cancer models. Its unique mechanism and validated workflows support highly reproducible, data-rich experimentation—especially when conventional LBD-targeting agents are insufficient.

• P2RX1-Mediated Apoptosis in Ph+ ALL: Mechanisms and Detectio

  2026-05-25

  This article reviews a recent study elucidating how P2RX1 promotes mitochondrial apoptosis via calcium/CaMKII-dependent inhibition of PI3K/Akt signaling in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The findings provide mechanistic insight into TKI response and suggest new directions for apoptosis detection and therapeutic targeting.

• Live-Dead Cell Staining Kit: Precision in Cell Viability Ass

  2026-05-25

  Harness dual Calcein-AM and Propidium Iodide staining for reliable, quantifiable live-dead distinction in advanced cell-based research. Explore optimized workflows, troubleshooting strategies, and direct protocol enhancements that set the APExBIO Live-Dead Cell Staining Kit apart for cytotoxicity, biomaterials, and wound healing studies.

• DiscoveryProbe Protease Inhibitor Library: Advanced HTS Work

  2026-05-24

  Harness the DiscoveryProbe Protease Inhibitor Library for robust, scalable modulation of protease activity in high-throughput and high-content assays. This guide translates validated research and practical troubleshooting into actionable protocols for apoptosis, cancer, and infectious disease studies.

• Laminin (925-933): Unlocking Cell Adhesion and Migration Pat

  2026-05-23

  This article provides a thought-leadership perspective on Laminin (925-933), a defined laminin B1 chain peptide, highlighting its mechanistic role in modulating cell adhesion and migration, its competitive positioning in translational research workflows, and strategic guidance for researchers bridging extracellular matrix biology with disease modeling. Integrating mechanistic science, protocol best practices, and translational outlook, this piece advances beyond typical product pages to discuss future directions in metastasis and neurodegeneration research.

• MDV3100 (Enzalutamide): Single-Cell Insights Into AR Inhibit

  2026-05-22

  Explore how MDV3100 (Enzalutamide) advances prostate cancer research by enabling single-cell level dissection of androgen receptor pathway inhibition, plasticity, and therapeutic resistance. This article unpacks new mechanistic insights and practical assay guidance beyond conventional approaches.

• Bardoxolone Methyl in Redox-Sensitive Oncology and Renal Mod

  2026-05-22

  Explore Bardoxolone methyl as a potent Nrf2 pathway modulator and NF-kB inhibitor in oxidative stress research. This article goes beyond standard protocol guides, providing original insight into redox-regulated assay design and translational applications.

• Tamoxifen as a Selective Estrogen Receptor Modulator: Protoc

  2026-05-21

  Tamoxifen empowers researchers with precise control over gene knockout and cancer model workflows, while also unlocking novel antiviral and immunology applications. This guide delivers stepwise protocols, troubleshooting strategies, and actionable insights derived from recent high-impact studies and peer best practices.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-05-21

  Schwartz's dissertation systematically dissects how anti-cancer drugs impact both cell proliferation and cell death, revealing that commonly used in vitro viability metrics may conflate these distinct processes. This work provides a more nuanced framework for interpreting drug responses, with direct implications for preclinical testing and rational anti-angiogenic therapy evaluation.

• Synergistic Statin and Erlotinib Cytotoxicity in NSCLC: Apop

  2026-05-20

  This study clarifies the cell death mechanisms induced by combining statins and erlotinib in EGFR TKI-resistant non-small cell lung cancer (NSCLC) cell lines. Through a systematic inhibitor approach, the research demonstrates that the synergistic cytotoxicity observed is mediated exclusively by apoptosis, not by ferroptosis or other regulated cell death pathways, providing a refined understanding for cancer biology research and therapeutic strategy development.

14473 records 4/965 page Previous Next 12345 下5页 Last page